Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

RSAD2‑YTHDF1 axis drives IBD via mitochondrial transfer

December 15, 2025

Researchers published a Nature Communications study identifying an RSAD2‑YTHDF1 signaling axis that promotes inflammatory bowel disease by enabling intercellular mitochondrial transfer from smooth...

HIV uses sialoglycans to evade myeloid attack – new mechanism

December 15, 2025

A Nature Communications paper revealed that HIV‑infected CD4+ T cells express sialoglycans that inhibit myeloid cell–mediated clearance, allowing infected cells to persist. The study mapped...

Trehalose‑6‑phosphate modulates Candida auris echinocandin resistance

December 15, 2025

A laboratory study found that accumulation of trehalose‑6‑phosphate (T6P) in Candida auris alters its susceptibility to echinocandin antifungals. The research team demonstrated biochemical and...

Bio‑adaptive hydrogel reconstructs trachea – Nature Communications advance

December 15, 2025

A Nature Communications team reported a bio‑adaptive physical hydrogel designed for dynamic tracheal reconstruction that interfaces mechanically with native tissue and supports epithelial...

AI and physics‑based modeling identify new Parkinson’s candidate — Gain Therapeutics

December 15, 2025

Gain Therapeutics disclosed an AI and physics‑based modeling approach that identified a small molecule allosteric binder which restores a dysfunctional enzyme and reduces neuroinflammation in...

Structure shares double: oral GLP‑1 Phase II sparks investor frenzy

December 14, 2025

Structure Therapeutics reported positive mid‑stage (Phase II ACCESS) data for its oral GLP‑1 candidate aleniglipron, driving a 102% one‑week share jump. The company presented placebo‑adjusted mean...

Laguna Bio deploys engineered Listeria: living drug enters pediatric leukemia pipeline

December 14, 2025

Laguna Bio disclosed a therapeutics program using a highly attenuated Listeria monocytogenes strain engineered to stimulate multifactorial immune responses and expand gamma delta T cells; the...

Deep learning predicts kidney transplant outcomes from procurement biopsies

December 14, 2025

Researchers published findings in Scientific Reports showing a deep learning model that rapidly analyses procurement kidney biopsies to predict transplant outcomes and assist pathology...

AI framework links drug biology to breast cancer response

December 14, 2025

A Nature Communications study unveiled a deep learning framework that integrates biologically informed drug representations to predict breast cancer responses across drug panels and molecular...

ALKBH5 inhibition strips colorectal tumors of stemness and chemoresistance

December 14, 2025

Nature Communications published a mechanistic study identifying the m6A RNA demethylase ALKBH5 as a driver of cancer stemness and chemoresistance in colorectal cancer; genetic or pharmacologic...

Targeting LRBA triggers CTLA‑4 degradation – a new immune‑checkpoint lever

December 14, 2025

Researchers reported in Nature Communications that inhibiting LRBA induces CTLA‑4 degradation and enhances anti‑tumor immunity in preclinical models. The study elucidates a pathway by which LRBA...

Blocking chaperone‑mediated autophagy targets glioblastoma stem cells, revives immunity

December 14, 2025

A new study identified chaperone‑mediated autophagy as essential for glioblastoma stem cell maintenance and showed that its inhibition both depletes stem‑like cells and reinvigorates anti‑tumor...

Human monoclonals neutralize clade 2.3.4.4b H5N1 – pandemic countermeasure advance

December 14, 2025

Nature Communications reported isolation of human monoclonal antibodies that potently neutralize clade 2.3.4.4b H5N1 hemagglutinin and block viral entry across multiple assays. The study...

HIV cloaks infected CD4+ T cells with sialoglycans to evade myeloid clearance

December 14, 2025

A Nature Communications study revealed that HIV‑infected CD4+ T cells upregulate sialoglycans on their surfaces to avoid phagocytic destruction by myeloid cells. The authors mapped the glycan...

c‑di‑GMP adjuvant sharpens TLR4‑based tuberculosis vaccine responses

December 14, 2025

Researchers reported preclinical evidence that c‑di‑GMP enhances TLR4‑targeted vaccine efficacy against Mycobacterium tuberculosis by amplifying innate sensing and adaptive responses. The study,...

Gene-edited cell transplant restores insulin production in patient

December 14, 2025

Scientists reported a first-in-human success: gene-edited, insulin-producing cells were transplanted into a man with type 1 diabetes and restored measurable endogenous insulin production without...

Laguna Bio’s living Listeria therapy readies pediatric leukemia trial

December 14, 2025

Laguna Bio is advancing an engineered, highly attenuated Listeria monocytogenes strain into clinical testing for pediatric leukemia after preclinical work showing robust activation of rare...

LRBA inhibition degrades CTLA‑4: a new lever for cancer immunity

December 14, 2025

Researchers published data showing that targeting LRBA triggers degradation of the immune checkpoint CTLA‑4 and enhances anti-tumor immune responses. The Nature Communications study characterizes...

ALKBH5 blockade curbs colorectal cancer stemness and resistance

December 14, 2025

A Nature Communications paper identified the m6A RNA demethylase ALKBH5 as a key maintainer of colorectal cancer stemness and chemoresistance and showed that ALKBH5 inhibition impairs...

Fucoidan enhances CAR‑T potency in lymphoma models

December 14, 2025

Preclinical work shows that fucoidan, a seaweed-derived polysaccharide, boosts CAR‑T cell efficacy against non-Hodgkin lymphoma in laboratory models. The study demonstrates that fucoidan augments...